Mereo BioPharma MREO Insider Ownership

NASDAQ MREO
$0.24 +0.00 (+0.87%)
At close: Sep 10, 2026 · 4:00 PM EDT

Insider Holdings by Owner

450.00K Shares

Insider Ownership Statistics

as of 30 Sep, 2026
Insider Ownership
0.0016%
0% pp QoQ
Shares Held by Insiders
12.55K
filed for Sep 2026
0.00% QoQ
Shares Outstanding
799.95Mn
799,947,013 shares
Direct Holdings
0
Indirect: 12.55K
Net Shares Traded (QoQ)
0
no net change in Sep 2026
Insiders Holding Shares
5
with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding
Latest
Average ownership
Peak ownership

Shares Purchased/Sold by Insiders

Bought Sold
Latest quarter
Net over range
Buying quarters

Insider Ownership Summary

Quarter ending 30 Sep, 2026

As of September 09, 2026, the three largest insider holders of MREO are Charles Sermon (General Counsel, 219.06K shares), Christine Ann Fox (Chief Financial Officer, 89.28K shares), John A. Lewicki (Chief Scientific Officer, 78.63K shares).

Form 4 Holdings

Insiders Holding MREO

Insiders 5
Shares held 450.00K
Of outstanding 0.056%
# Insider Position Direct Indirect Total Share of Insiders Last Filed
1 Charles Sermon General Counsel 219,061 0 219,061 48.7% 16 Sep, 2024
2 Christine Ann Fox Chief Financial Officer 89,285 0 89,285 19.8% 16 Sep, 2024
3 John A. Lewicki Chief Scientific Officer 78,630 0 78,630 17.5% 16 Sep, 2024
4 Alexandra Hughes-Wilson Officer 50,475 0 50,475 11.2% 16 Sep, 2024
5 Jeremy Bender Director 0 12,550 12,550 2.8% 17 Jun, 2024

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

138 Insider Transactions

Source SEC Form 4
Latest quarter Sep 2026
Download Data
Date Insider Position Transaction Shares Price Value Shares Held After Ownership
26 Feb, 2026 Daniel Shames Director Acquired A 66,000 $0.00 $0 66,000 Direct
26 Feb, 2026 Pierre Jacquet Director Acquired A 66,000 $0.00 $0 66,000 Direct
26 Feb, 2026 Daniel Shames Director Acquired A 66,000 $0.00 $0 66,000 Direct
26 Feb, 2026 Jeremy Bender Director Acquired A 66,000 $0.00 $0 66,000 Direct
26 Feb, 2026 Daniel Shames Director Acquired A 66,000 $0.00 $0 66,000 Direct
26 Feb, 2026 Anders Ekblom Director Acquired A 66,000 $0.00 $0 66,000 Direct
26 Feb, 2026 Annalisa Jenkins Director Acquired A 66,000 $0.00 $0 66,000 Direct
26 Feb, 2026 Daniel Shames Director Acquired A 96,163 96,163 Direct
26 Feb, 2026 Daniel Shames Director Acquired A 96,163 96,163 Direct
26 Feb, 2026 Anders Ekblom Director Acquired A 133,560 133,560 Direct
26 Feb, 2026 Pierre Jacquet Director Acquired A 106,848 106,848 Direct
26 Feb, 2026 Annalisa Jenkins Director Acquired A 106,848 106,848 Direct
26 Feb, 2026 Jeremy Bender Director Acquired A 117,533 117,533 Direct
26 Feb, 2026 Daniel Shames Director Acquired A 96,163 96,163 Direct
01 Feb, 2026 Alexandra Hughes-Wilson Officer Acquired A 183,750 $0.00 $0 183,750 Direct
01 Feb, 2026 Charles Sermon General Counsel Acquired A 315,750 $0.00 $0 315,750 Direct
01 Feb, 2026 Christine Ann Fox Chief Financial Officer Acquired A 315,750 $0.00 $0 315,750 Direct
01 Feb, 2026 Charles Sermon General Counsel Acquired A 315,750 $0.00 $0 315,750 Direct
01 Feb, 2026 John A. Lewicki Chief Scientific Officer Acquired A 139,913 $0.00 $0 139,913 Direct
01 Feb, 2026 Charles Sermon General Counsel Acquired A 315,750 $0.00 $0 315,750 Direct